Investing in Cures for Cancer: GE Poised to Lead Industrialization of Cell Therapy Industry with Acquisition of Biosafe Group...
July 13 2016 - 9:00AM
Business Wire
Acquisition further develops integrated cell therapy and
regenerative medicine offering to enable development and patient
access to innovative life-saving therapies
GE Healthcare has acquired Biosafe Group SA, a supplier of
integrated cell bioprocessing systems for the rapidly growing cell
therapy and regenerative medicine industry for an undisclosed sum.
The acquisition of Biosafe expands GE Healthcare’s end-to-end
ecosystem of products, solutions and services for our cell therapy
customers, and expands GE’s technology reach to a number of new
cell and therapy types.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160713005783/en/
Cellular therapies are rapidly changing the healthcare landscape
by providing life-saving and potentially curative treatments for
many of the world’s most challenging diseases, especially cancer.
The cell therapy oncology market alone is expected to reach $30
billion by 20301 with more than 600 potentially life-changing
therapies in clinical trials at the end of 20152.
Biosafe, headquartered in the Lake Geneva region in Switzerland,
with a global presence, has a 20 year track-record in automated
cell processing and is a recognized leader in the field with
reliable applications in bioprocessing, regenerative medicine and
stem cell banking. Its proprietary products offer significant
advantages over conventional processing tools, with closed fluid
pathways, built-in traceability and single-use consumables. The
strong strategic fit and complementary business models of GE
Healthcare’s Life Sciences business and Biosafe combined with
expanded capabilities in product development and commercial reach,
will offer significant customer and ultimately patient
benefits.
Kieran Murphy, CEO Life Sciences, GE Healthcare said: “GE is
building a world-class set of tools, technologies and services for
cell and gene therapy and Biosafe’s expertise and innovative
systems will strongly enhance our customer offering. GE and Biosafe
share a vision of an integrated approach to helping customers
optimize every stage of their process to reduce production risks
dramatically and increase access to these remarkable new
medicines.”
Claude Fell, Founder and Chairman, Biosafe Group SA, said:
“Together with GE we will have the combination of biological,
engineering and industrial capabilities to help accelerate the
fields of cell therapy and cellular immunotherapy into the
mainstream, benefitting patients globally, and bringing the vision
of personalized medicine to reality.” Olivier Waridel, Biosafe CEO,
who will continue to lead Biosafe within the new integrated GEHC
structure, added: “Joining GE Healthcare will give Biosafe an
outstanding opportunity to couple its unique cell processing
technology with GE Healthcare’s strong, global infrastructure,
leading to improved capabilities for our customers and enhanced
market penetration.”
GE’s strategy is to work with the industry and partners to
develop a digitally-enabled ecosystem of complete tools, solutions
and services for cell therapy aimed at accelerating the
standardization, collaboration and integration customers need to
bring these new therapies into mainstream clinical practice. GE has
engaged globally with leaders in the industry, such as Canada’s
Center for the Commercialization of Regenerative Medicine, the UK’s
Cell and Gene Therapy Catapult, Australia’s Cell Therapy
Manufacturing Cooperative Research Centre and leading clinical
centers such as UPenn, Karolinska Institute, Memorial
Sloan-Kettering and Mayo Clinic.
In 2016, GE has announced further significant investments in the
cell therapy and regenerative medicine space. In April, GE Ventures
and Mayo Clinic announced the launch of Vitruvian Networks, Inc.,
an independent platform company committed to accelerating access to
cell and gene therapies through advanced, cloud-ready software
systems and manufacturing services. In January, GE announced the
BridGE@CCRM Cell Therapy Centre of Excellence, a US $31.5 million
co-investment with the Canadian Government to promote new
technologies for the production of cellular therapies in
Toronto.
*END*
About GE Healthcare
GE Healthcare provides transformational medical technologies and
services to meet the demand for increased access, enhanced quality
and more affordable healthcare around the world. GE (NYSE: GE)
works on things that matter - great people and technologies taking
on tough challenges. From medical imaging, software & IT,
patient monitoring and diagnostics to drug discovery,
biopharmaceutical manufacturing technologies and performance
improvement solutions, GE Healthcare helps medical professionals
deliver great healthcare to their patients. For more information
about GE Healthcare, visit our website at www.gehealthcare.com.
About Biosafe Group SA
Founded in 1997 the Biosafe Group is active in the design,
manufacture and marketing of automated cell processing systems.
Headquartered in Switzerland and privately-owned, the
Biosafe Group operates through regional subsidiaries
(Geneva, Houston, Hong-Kong, Shanghai and São Paulo)
and is present in more than 50 countries, either directly or
through distributors. For more information about Biosafe, visit the
website www.biosafe.ch.
1
http://www.centerwatch.com/news-online/2015/10/23/t-cell-immunotherapy-market-may-be-worth-30b-by-2030/
2 Alliance for Regenerative Medicine Q1 Data Report 2016
http://alliancerm.org/page/arm-data-reports#
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160713005783/en/
GE HealthcareErin BryantErin.Bryant@ge.com+1 203 450
5326@GEHealthcare
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Mar 2024 to Apr 2024
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Apr 2023 to Apr 2024